Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02962765 · ClinicalTrials.gov registry record
Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
A clinical trial, sponsored by Octapharma.
- Completed
- Registry status
- 80
- Enrollment target
NCT02962765 is a clinical trial that has completed, run by Octapharma. The registered enrollment target is 80 participants.
The verdict
NCT02962765 has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
Prospective, multinational, non-interventional post-authorisation study to collect additional clinical data and to ensure consistency in the long-term between the outcome from pre-authorisation clinical studies (in 135 previously treated paediatric and adult patients) and routine clinical practice. Besides aspects such as general product safety and efficacy, there will be a focus on immunogenicity, particularly on inhibitor development. The diagnosis of FVIII inhibitor will be based on clinical observations and confirmed by FVIII inhibitor testing in the laboratory.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-01 |
| Est. Completion | 2020-08-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02962765
The ClinicalTrials.gov registry entry for NCT02962765 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02962765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02962765 about?
NCT02962765 is a clinical study titled "Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ". Prospective, multinational, non-interventional post-authorisation study to collect additional clinical data and to ensure consistency in the long-term between the outcome from pre-authorisation clinical studies (in 135 previously treated paediatric and adult patients) and routine clinical practice. ...
What is the current status of trial NCT02962765?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2015-01. Estimated completion is 2020-08-20.
Who is sponsoring clinical trial NCT02962765?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.